Search Results

Vasomune Therapeutics, Inc., has announced today that the US Food and Drug Administration (FDA) granted Fast Track designation for AV-001 for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections.

Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.

Vasomune Therapeutics, Inc. has been selected by the American Thoracic Society to showcase its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit (RIS).

Vasomune Therapeutics and AnGes drug candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study.

Vasomune Receives a US $6.4 Million PRMRP Grant from the US Department of Defense and up to $2.8 Million from NRC IRAP to Support the Development of AV-001 for the Treatment of Patients with Severe COVID-19 Disease and COVID-associated ARDS

Vasomune Therapeutics, Inc. announced today it has dosed the first patient in the Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease.

AV-001 was Safe and Well-Tolerated in Healthy Volunteers Vasomune plans to initiate a Phase 2a proof-of-concept study following review with FDA to assess safety and efficacy in patients with severe COVID-19 disease

Industry Leader Joins Vasomune’s Board of Directors as the Company Transitions to Clinical Development of AV-001 for the Treatment of COVID-19/pathogen-induced ARDS TORONTO--( BUSINESS WIRE )-- Vasomune Therapeutics, Inc., an early stage therapeutic biopharmaceutical company developing a novel first-in-class medicine for the treatment of COVID-19/pathogen-induced ARDS, today announced the appointment of Meenu Chhabra to the Company’s Board of Direct

Vasomune Therapeutics, Inc., a therapeutic biopharmaceutical company developing a novel first-in-class medicine for the treatment of COVID-19 pneumonia and pathogen-induced ARDS, today announced the formation of a Clinical and Scientific Advisory Board. The Board is composed of key opinion leaders in their respective fields of medicine and

Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for AV-001, a Tie2 tyrosine kinase receptor agonist, as a potential treatment for hospitalized patients diagnosed with moderate-to-severe COVID-19 disease.